Shanghai Jiaotong University-a pawl pakhatin zirchianna an neihah formic acid hi zun biomarker sensitive tak a ni a, Alzheimer’s disease (AD) hi a hmaa hriat theih a ni. He thil hmuhchhuah hian mass screening man tlawm leh awlsam zawka kalpui theihna kawng a hawnsak thei a ni. Dr. Yifan Wang, Dr. Qihao Guo leh a thawhpuiten Frontiers in Aging Neuroscience-ah “Systematic Evaluation of Formic Acid in Urine as a New Potential Alzheimer’s Biomarker” tih thupui hmangin thuziak an tichhuak a. An thusawiah hian ziaktute chuan heti hian an thutlukna an siam a, “Urine-a formic acid hian Alzheimer natna screening hmasa ber atan sensitivity tha tak a nei a... Zun atanga Alzheimer’s disease biomarker hmuhchhuah hi a awlsamin a man a to hle a, tarte damdawi lam enfiahna pangngaiah pawh telh tur a ni,” tiin an sawi.
Hemi ziaktute hian AD, dementia natna tlanglawn ber chu hriatna leh nungchang lama harsatna nasa tak a awm tih an sawifiah a. AD natna thlentu ber chu extracellular amyloid β (Aβ) a awm dan pangngai lo, neurofibrillary tau tangles a awm dan pangngai lo, leh synapse tihchhiat te hi a ni. Mahse, team chuan, “AD natna thlen dan hi hriat chian a la ni lo,” tiin an sawi chhunzawm a ni.
Alzheimer natna hi enkawl a tlai hma loh chuan hriat lohvin a awm thei a ni. “Natna rei tak awm reng leh insidious tak a ni a, chu chu overt cognitive impairment a lo lan hmain kum tam tak chhung a lo awm thei a, a awm reng thei tihna a ni,” tiin ziaktute chuan an sawi. “He natna hmasa ber hi irreversible dementia stage hmaa thleng a ni a, hei hi intervention leh enkawlna atana rangkachak window a ni. Chuvangin, tarte zingah Alzheimer’s natna hmasa berte screening lian tak neih a ngai a ni.”.
Mass screening programme hian natna hi a tir lamah hriatchhuahna kawngah a puih laiin, tuna diagnostic method hman mek hi a buaithlak lutuk a, routine screening atan chuan a man a to hle. Positron emission tomography-computed tomography (PET-CET) hian Aβ deposit hmasa berte chu a hmuchhuak thei a, mahse a man a to a, damlote chu radiation-ah a hruai lut a, Alzheimer’s natna hriat theihna tura puitu biomarker test-ah chuan cerebrospinal fluid hmuh theih nan invasive blood draw emaw lumbar puncture emaw a ngai a, hei hi damlote tan chuan a repulsive thei a ni.
Zirchiangtute chuan zirchianna engemaw zatah chuan AD vei urinary biomarker awm leh awm loh screen theih a nih thu an sawi. Urinalysis hi non-invasive leh awlsam tak a nih avangin mass screening atan a tha hle. Mahse scientist-te chuan AD awmna tur urinary biomarker an lo hmuchhuak tawh a, mahse natna hmasa ber hriat theihna tur pakhat mah a tling lo a, hei hian enkawl hmasakna tur rangkachak window chu hmuh theih a la ni lo tihna a ni.
Wang leh a thawhpuiten a hmain formaldehyde hi Alzheimer natna atana urinary biomarker atan an lo zirchiang tawh a ni. “Tun hnaiah chuan formaldehyde metabolism pangngai lo chu kum upat avanga hriatna lama harsatna thlentu ber pakhat a nih thu hriat a ni,” an ti. “Kan zirchianna hmasa khan urinary formaldehyde level leh cognitive function inzawmna a awm tih kan report a, hei hian urinary formaldehyde hi AD natna hriat hmasakna atana biomarker awm thei a nih thu a tarlang a ni.”.
Mahse, natna hriat hmasakna atana biomarker atana formaldehyde hman hi hmasawnna tur a awm. Tun hnaia an zirchianna an tihchhuahah hian he team hian formaldehyde metabolite formate chu biomarker anga a thawk tha zawk em tih an enfiah a ni.
Study group-ah hian mi 574 an tel a, chung zingah chuan Alzheimer natna nasat dan inang lo vei te bakah cognitively normal healthy control-a telte pawh an tel a ni. He zirchiannaah hian zirchiangtute hian zun leh thisen sample te chu an zirchiang a, zun biomarker-a danglamna an zawng a, psychological assessment an nei bawk. He huna telte hi an diagnosis a zirin group pangaah ṭhen an ni a, chungte chu cognitively normal (NC) mi 71, subjective cognitive decline (SCD) 101, no mild cognitive impairment (CINM), cognitive impairment 131, mild cognitive impairment (MCI) mi 158, leh 113 BA nei. .
He zirchianna hian Alzheimer’s disease group zawng zawngah urinary formic acid level a sang hle tih hmuhchhuah a ni a, healthy controls te nena khaikhin chuan cognitive decline nen a inzawm tih hmuhchhuah a ni a, early subjective cognitive decline group pawh a tel. Hei hian formic acid hi AD natna hmasa ber atan sensitive biomarker angin a thawk thei tih a tilang. “He zirchiannaah hian a vawi khat nan urinary formic acid level hi cognitive decline nen a inthlak tih kan report a ni,” an ti. “Urine formic acid hian AD hriatchhuahna kawngah a thawhhlawkzia danglam tak a lantir a, hei bakah hian SCD diagnosis group-ah hian urinary formic acid hi nasa takin a pung a, hei hian urinary formic acid hi AD natna hriat hmasak nan hman theih a ni tihna a ni.”
Ngaihven awm tak chu, zirchiangtute hian thisen Alzheimer’s biomarker nena inzawm urine formate level an zirchian chuan damlote natna dinhmun dik zawk an sawi thei tih an hmuchhuak a ni. Mahse, Alzheimer natna leh formic acid inzawmna hriat chian nan zirchianna neih belh a ngai a ni.
Mahse, ziaktute chuan heti hian thutlukna an siam a: “Urine formate leh formaldehyde level hi AD leh NC thliar hrangna atan chauh ni lovin, AD natna stage atana plasma biomarker-te predictive accuracy tihchangtlun theih a ni bawk. potential biomarkers for diagnosis”.